• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝素通过影响Wnt信号通路拮抗A2780卵巢癌细胞的顺铂耐药性。

Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.

作者信息

Pfankuchen Daniel Bastian, Baltes Fabian, Batool Tahira, Li Jin-Ping, Schlesinger Martin, Bendas Gerd

机构信息

Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.

Department of Medical Biochemistry and Microbiology, SciLifeLab, University of Uppsala, Uppsala, Sweden.

出版信息

Oncotarget. 2017 Jun 28;8(40):67553-67566. doi: 10.18632/oncotarget.18738. eCollection 2017 Sep 15.

DOI:10.18632/oncotarget.18738
PMID:28978053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5620193/
Abstract

Low molecular weight heparin (LMWH), the guideline based drug for prophylaxis and treatment of cancer-associated thrombosis, was recently shown to sensitize cisplatin resistant A2780cis human ovarian cancer cells for cisplatin cytotoxicity upon 24 h pretreatment with 50 μg × mL of the LMWH tinzaparin , equivalent to a therapeutic dosage. Thereby, LMWH induced sensitization by transcriptional reprogramming of A2780cis cells via not yet elucidated mechanisms that depend on cellular proteoglycans. Here we aim to illuminate the underlying molecular mechanisms of LMWH in sensitizing A2780cis cells for cisplatin. Using TCF/LEF luciferase promotor assay (Top/Flash) we show that resistant A2780cis cells possess a threefold higher Wnt signaling activity compared to A2780 cells. Furthermore, Wnt pathway blockade by FH535 leads to higher cisplatin sensitivity of A2780cis cells. Glypican-3 (GPC3) is upregulated in A2780cis cells in response to LMWH treatment, probably as counter-regulation to sustain the high Wnt activity against LMWH. Hence, LMWH reduces the cisplatin-induced rise in Wnt activity and TCF-4 expression in A2780cis cells, but keeps sensitive A2780 cells unaffected. Consequently, Wnt signaling pathway appears as primary target of LMWH in sensitizing A2780cis cells for cisplatin toxicity. Considering the outstanding role of LMWH in clinical oncology, this finding appears as promising therapeutic option to hamper chemoresistance.

摘要

低分子量肝素(LMWH)是预防和治疗癌症相关血栓形成的指南推荐药物,最近有研究表明,用相当于治疗剂量的50μg×mL的LMWH替扎肝素预处理24小时后,可使顺铂耐药的A2780cis人卵巢癌细胞对顺铂的细胞毒性敏感。因此,LMWH通过尚未阐明的依赖细胞蛋白聚糖的机制对A2780cis细胞进行转录重编程,从而诱导敏感性。在此,我们旨在阐明LMWH使A2780cis细胞对顺铂敏感的潜在分子机制。使用TCF/LEF荧光素酶启动子分析(Top/Flash),我们发现耐药的A2780cis细胞的Wnt信号活性比A2780细胞高3倍。此外,FH535阻断Wnt通路可导致A2780cis细胞对顺铂的敏感性更高。硫酸乙酰肝素蛋白聚糖-3(GPC3)在A2780cis细胞中因LMWH处理而上调,可能作为一种反调节来维持针对LMWH的高Wnt活性。因此,LMWH降低了顺铂诱导的A2780cis细胞中Wnt活性和TCF-4表达的升高,但对敏感的A2780细胞没有影响。因此,Wnt信号通路似乎是LMWH使A2780cis细胞对顺铂毒性敏感的主要靶点。考虑到LMWH在临床肿瘤学中的突出作用,这一发现似乎是一种有前景的克服化疗耐药性的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/bdf5a9a1acbb/oncotarget-08-67553-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/47e88219b262/oncotarget-08-67553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/8a8874208192/oncotarget-08-67553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/fcbe8b798797/oncotarget-08-67553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/4aaf36686ea7/oncotarget-08-67553-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/dfb49b01e302/oncotarget-08-67553-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/e1595d86478a/oncotarget-08-67553-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/c450a800a629/oncotarget-08-67553-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/bdf5a9a1acbb/oncotarget-08-67553-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/47e88219b262/oncotarget-08-67553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/8a8874208192/oncotarget-08-67553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/fcbe8b798797/oncotarget-08-67553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/4aaf36686ea7/oncotarget-08-67553-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/dfb49b01e302/oncotarget-08-67553-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/e1595d86478a/oncotarget-08-67553-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/c450a800a629/oncotarget-08-67553-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f393/5620193/bdf5a9a1acbb/oncotarget-08-67553-g008.jpg

相似文献

1
Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.肝素通过影响Wnt信号通路拮抗A2780卵巢癌细胞的顺铂耐药性。
Oncotarget. 2017 Jun 28;8(40):67553-67566. doi: 10.18632/oncotarget.18738. eCollection 2017 Sep 15.
2
The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.低分子量肝素替扎肝素对顺铂耐药卵巢癌致敏作用的研究——异种移植肿瘤模型的临床前体内评估
Molecules. 2017 May 3;22(5):728. doi: 10.3390/molecules22050728.
3
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.低分子量肝素丁那肝素拮抗顺铂耐药的卵巢癌细胞。
Biochem Pharmacol. 2015 Sep 15;97(2):147-57. doi: 10.1016/j.bcp.2015.07.013. Epub 2015 Jul 31.
4
Inhibition of coiled coil domain containing protein 69 enhances platinum-induced apoptosis in ovarian cancer cells.抑制卷曲螺旋结构域包含蛋白69可增强铂诱导的卵巢癌细胞凋亡。
Oncotarget. 2017 Sep 28;8(60):101634-101648. doi: 10.18632/oncotarget.21356. eCollection 2017 Nov 24.
5
Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.雷帕霉素在体外和体内均增强了奥沙利铂对顺铂耐药卵巢癌细胞A2780cis的抗肿瘤疗效。
J Chemother. 2015;27(6):358-64. doi: 10.1179/1973947815Y.0000000021. Epub 2015 May 15.
6
Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells.细胞外 ATP 对顺铂诱导的人卵巢癌细胞毒性的影响。
Chemotherapy. 2010;56(1):1-8. doi: 10.1159/000287351. Epub 2010 Feb 24.
7
How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cells.脂质体顺铂如何克服卵巢肿瘤细胞的化疗耐药性。
Anticancer Res. 2014 Jan;34(1):525-30.
8
Nano-mechanical reinforcement in drug-resistant ovarian cancer cells.耐药性卵巢癌细胞中的纳米机械增强作用。
Biol Pharm Bull. 2015;38(3):389-95. doi: 10.1248/bpb.b14-00604.
9
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.鉴定卵巢癌中与化疗耐药相关的新型缺氧标志物。
BMC Cancer. 2015 Jul 25;15:547. doi: 10.1186/s12885-015-1539-8.
10
High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.含金刚烷胺的铂(IV)配合物在体外克服顺铂耐药性及抑制卵巢癌细胞增殖方面具有高效性。
Biochem Pharmacol. 2005 Feb 1;69(3):373-83. doi: 10.1016/j.bcp.2004.09.005. Epub 2004 Dec 23.

引用本文的文献

1
Identification of FLYWCH1 as a regulator of platinum-resistance in epithelial ovarian cancer.鉴定FLYWCH1为上皮性卵巢癌铂耐药的调节因子。
NAR Cancer. 2025 Apr 4;7(2):zcaf012. doi: 10.1093/narcan/zcaf012. eCollection 2025 Jun.
2
Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.非抗凝肝素:口腔癌新型治疗方法的体外研究
Oral Dis. 2025 Jun;31(6):1672-1683. doi: 10.1111/odi.15288. Epub 2025 Mar 3.
3
Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy.

本文引用的文献

1
The regulation of β-catenin activity and function in cancer: therapeutic opportunities.β-连环蛋白活性和功能在癌症中的调控:治疗机遇
Oncotarget. 2017 May 16;8(20):33972-33989. doi: 10.18632/oncotarget.15687.
2
Effect of miR-212 targeting TCF7L2 on the proliferation and metastasis of cervical cancer.靶向TCF7L2的miR-212对宫颈癌增殖和转移的影响
Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):219-226.
3
Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca pathways in cisplatin-induced chemoresistance in ovarian cancer.
抗凝治疗对恶性肿瘤患者的抗炎和抗癌作用
Life (Basel). 2023 Sep 10;13(9):1888. doi: 10.3390/life13091888.
4
The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.注射剂在癌症相关血栓形成的治疗和预防中的作用。
Cancers (Basel). 2023 Sep 20;15(18):4640. doi: 10.3390/cancers15184640.
5
Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling.外切体蛋白 1 敲低通过上调 JNK 和 MEK/ERK 信号诱导 MV3 黑素瘤细胞的化疗耐药性。
Int J Mol Sci. 2023 Mar 13;24(6):5452. doi: 10.3390/ijms24065452.
6
Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells.肝素及基于肝素的药物递送系统:对骨肉瘤和免疫细胞多药耐药性的多效性分子效应
Pharmaceutics. 2022 Oct 13;14(10):2181. doi: 10.3390/pharmaceutics14102181.
7
Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma.聚焦于卵巢透明细胞癌相关高凝状态的治疗策略
Cancers (Basel). 2022 Apr 24;14(9):2125. doi: 10.3390/cancers14092125.
8
Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β-integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding.靶向细胞表面糖蛋白 Discoidin domain receptor 1(DDR1)及其与β整合素的相互作用,结合Ⅰ型胶原,成为乳腺癌化疗增敏的关键因素。
Int J Mol Sci. 2020 Jul 13;21(14):4956. doi: 10.3390/ijms21144956.
9
Effects of Wnt/β-Catenin Signal Pathway Regulated by miR-342-5p Targeting CBX2 on Proliferation, Metastasis and Invasion of Ovarian Cancer Cells.miR-342-5p靶向CBX2调控Wnt/β-连环蛋白信号通路对卵巢癌细胞增殖、转移及侵袭的影响
Cancer Manag Res. 2020 May 21;12:3783-3794. doi: 10.2147/CMAR.S250208. eCollection 2020.
10
H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1α,25(OH)2D3) in Ovarian Cancer Biology.H3K4me3是骨化三醇(1α,25(OH)₂D₃)在卵巢癌生物学中抗增殖作用的潜在介导因子。
Int J Mol Sci. 2020 Mar 20;21(6):2151. doi: 10.3390/ijms21062151.
Wnt/β-连环蛋白、Wnt/c-Jun氨基末端激酶和Wnt/Ca信号通路在顺铂诱导的卵巢癌化疗耐药中的作用
Exp Ther Med. 2016 Dec;12(6):3851-3858. doi: 10.3892/etm.2016.3885. Epub 2016 Nov 8.
4
microRNA-328 inhibits cervical cancer cell proliferation and tumorigenesis by targeting TCF7L2.微小RNA-328通过靶向TCF7L2抑制宫颈癌细胞增殖和肿瘤发生。
Biochem Biophys Res Commun. 2016 Jun 24;475(2):169-75. doi: 10.1016/j.bbrc.2016.05.066. Epub 2016 May 13.
5
The Wnt signaling pathway in cancer.癌症中的Wnt信号通路。
Crit Rev Oncol Hematol. 2016 Mar;99:141-9. doi: 10.1016/j.critrevonc.2015.12.005. Epub 2015 Dec 24.
6
Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.随机 III 期临床试验:标准治疗联合低分子肝素治疗肺癌患者:FRAGMATIC 试验。
J Clin Oncol. 2016 Feb 10;34(5):488-94. doi: 10.1200/JCO.2015.64.0268. Epub 2015 Dec 23.
7
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.β-连环蛋白通路激活作为表皮生长因子受体靶向药物耐药患者的新靶点
Sci Rep. 2015 Aug 13;5:13076. doi: 10.1038/srep13076.
8
Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy.乙酰肝素酶通过促进自噬增强肿瘤生长和化疗耐药性。
Cancer Res. 2015 Sep 15;75(18):3946-57. doi: 10.1158/0008-5472.CAN-15-0037. Epub 2015 Aug 6.
9
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.低分子量肝素丁那肝素拮抗顺铂耐药的卵巢癌细胞。
Biochem Pharmacol. 2015 Sep 15;97(2):147-57. doi: 10.1016/j.bcp.2015.07.013. Epub 2015 Jul 31.
10
Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?癌症患者的抗凝治疗:患者选择会提高总生存率吗?
Thromb Haemost. 2015 Aug 31;114(3):530-6. doi: 10.1160/TH15-02-0124. Epub 2015 May 21.